|
Post by falconquest on Apr 8, 2019 19:25:36 GMT -5
Kelly Kraft from MannKind (15 years) just joined RLS > Check her LinkedIn page! .....and don't forget they have our Technosphere champion, Andrea Leone-Bay.
|
|
|
Post by awesomo on Apr 8, 2019 19:41:08 GMT -5
Is this our RLS??? Looks like it might be a different company. Receptor Holdings is the parent company, Receptor Life Sciences is a subsidiary.
|
|
|
Post by mango on Apr 8, 2019 19:48:33 GMT -5
Is this our RLS??? Looks like it might be a different company.
It's for a consulting firm and owner name is Receptor Holdings, Inc. 3211 W. McGraw St. Seattle, Washington 98139.
Not Receptor Life Sciences, Inc. CORPORATION WASHINGTON 2578 Constance Drive W Seattle WASHINGTON 98199
Same co. RLS is a subsidiary of Receptor Holdings
|
|
|
RLS
Apr 9, 2019 9:28:13 GMT -5
Post by bigchungus91354 on Apr 9, 2019 9:28:13 GMT -5
Coming out of the dark. We have seen 1/100th of the contract milestone cash. Bodes well for SP.
|
|
|
Post by kimi on Apr 10, 2019 4:18:29 GMT -5
|
|
|
RLS
Apr 15, 2019 8:57:40 GMT -5
Post by bigchungus91354 on Apr 15, 2019 8:57:40 GMT -5
Kelly Kraft from MannKind (15 years) just joined RLS > Check her LinkedIn page! .....and don't forget they have our Technosphere champion, Andrea Leone-Bay. So what is the plan, is RLS a life raft for MNKD employees to swim out to while CEO sinks the ship?
|
|
|
Post by #NoMoreNeedles on Apr 15, 2019 9:01:17 GMT -5
RLS in pre-IND phase. 3-5 years before they get any product onto the market (FDA approval required).
|
|
|
RLS
Apr 15, 2019 10:25:42 GMT -5
Post by bigchungus91354 on Apr 15, 2019 10:25:42 GMT -5
RLS in pre-IND phase. 3-5 years before they get any product onto the market (FDA approval required). Looks like a dud for the short-term.
|
|
|
Post by mango on May 9, 2019 12:35:48 GMT -5
|
|
|
Post by tw12 on May 9, 2019 14:58:21 GMT -5
In the "claims" section in these applications, at the end, is Claim #54.
Giving it a quick read is a good way to maintain enthusiasm for the astonishing breadth of TS applications:
"54. A method of reducing or eliminating one or more symptoms of a disease or disorder in a human subject, wherein said method includes delivering a therapeutically effective amount of a composition of claim 3 to the subject, thereby reducing or eliminating one or more symptoms of the disease or disorder, and wherein said disease or disorder is acquired hypothyroidism, acute gastritis, addiction, ADHD, agoraphobia, AIDS, AIDS-related anorexia, alcoholism, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), ankyloses, anxiety, arthritis, Asperger's syndrome, asthma, atherosclerosis, autism, auto-immune diseases, bacterial infections, bipolar disorder, bone loss, blood disorders, brain injury/stroke, cachexia, cancer, carpal tunnel syndrome, cerebral palsy, cervical disk disease, cervicobrachial syndrome, chronic fatigue syndrome, chronic pain, cluster headache, conjunctivitis, Crohn's disease, cystic fibrosis, depression, dermatitis, diabetes, dystonia, eating disorders, eczema, epilepsy, fever, fibromyalgia, flu, fungal infection, gastrointestinal disorders, glaucoma, glioma, Grave's disease, heart disease hepatitis, herpes, Huntington's disease, hypertension, impotence, incontinence, infant mortality, inflammation, inflammatory bowel disease (IBD), insomnia, liver fibrosis, mad cow disease, menopause, metabolic disorders, migraine headaches, motion sickness, MRSA, multiple sclerosis (MS), muscular dystrophy, mucosal lesions, nail patella syndrome, nausea and vomiting associated with cancer chemotherapy, neuroinflammation, nicotine addiction, obesity, obsessive compulsive disorder (OCD), osteoporosis, osteopenia, pain, pancreatitis, panic disorder, Parkinson's disease, periodontal disease, peripheral neuropathy, phantom limb pain, poison ivy allergy, premenstrual syndrome (PMS), proximal myotonic myopathy, post-traumatic stress disorder (PTSD), psoriasis, Raynaud's disease, restless leg syndrome, schizophrenia, scleroderma, septic shock, shingles herpes zoster), sickle cell disease, seizures, sleep apnea, sleep disorders, spinal injuries, stress, stuttering, temporomandibular joint disorder (TMJ), tension headaches, tinnitus, Tourette's syndrome, traumatic memories, wasting syndrome, or withdrawal syndrome."
Not too shabby. It's fun to imagine how many of these approximately 120 diseases and disorders -- five or ten years from now -- might well be treated with TS...
|
|
|
RLS
May 9, 2019 17:18:13 GMT -5
Post by lennymnkd on May 9, 2019 17:18:13 GMT -5
What exactly is the claim #54 post ... potential applications for technosphere ... can anyone share some color on this post .. sound like it can be pretty important.
|
|
|
Post by peppy on May 9, 2019 17:24:15 GMT -5
What exactly is the claim #54 post ... potential applications for technosphere ... can anyone share some color on this post .. sound like it can be pretty important. RLS technosphere potential treatment list.
|
|
|
RLS
May 9, 2019 18:31:51 GMT -5
Post by ktim on May 9, 2019 18:31:51 GMT -5
In the "claims" section in these applications, at the end, is Claim #54. Giving it a quick read is a good way to maintain enthusiasm for the astonishing breadth of TS applications: "54. A method of reducing or eliminating one or more symptoms of a disease or disorder in a human subject, wherein said method includes delivering a therapeutically effective amount of a composition of claim 3 to the subject, thereby reducing or eliminating one or more symptoms of the disease or disorder, and wherein said disease or disorder is acquired hypothyroidism, acute gastritis, addiction, ADHD, agoraphobia, AIDS, AIDS-related anorexia, alcoholism, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), ankyloses, anxiety, arthritis, Asperger's syndrome, asthma, atherosclerosis, autism, auto-immune diseases, bacterial infections, bipolar disorder, bone loss, blood disorders, brain injury/stroke, cachexia, cancer, carpal tunnel syndrome, cerebral palsy, cervical disk disease, cervicobrachial syndrome, chronic fatigue syndrome, chronic pain, cluster headache, conjunctivitis, Crohn's disease, cystic fibrosis, depression, dermatitis, diabetes, dystonia, eating disorders, eczema, epilepsy, fever, fibromyalgia, flu, fungal infection, gastrointestinal disorders, glaucoma, glioma, Grave's disease, heart disease hepatitis, herpes, Huntington's disease, hypertension, impotence, incontinence, infant mortality, inflammation, inflammatory bowel disease (IBD), insomnia, liver fibrosis, mad cow disease, menopause, metabolic disorders, migraine headaches, motion sickness, MRSA, multiple sclerosis (MS), muscular dystrophy, mucosal lesions, nail patella syndrome, nausea and vomiting associated with cancer chemotherapy, neuroinflammation, nicotine addiction, obesity, obsessive compulsive disorder (OCD), osteoporosis, osteopenia, pain, pancreatitis, panic disorder, Parkinson's disease, periodontal disease, peripheral neuropathy, phantom limb pain, poison ivy allergy, premenstrual syndrome (PMS), proximal myotonic myopathy, post-traumatic stress disorder (PTSD), psoriasis, Raynaud's disease, restless leg syndrome, schizophrenia, scleroderma, septic shock, shingles herpes zoster), sickle cell disease, seizures, sleep apnea, sleep disorders, spinal injuries, stress, stuttering, temporomandibular joint disorder (TMJ), tension headaches, tinnitus, Tourette's syndrome, traumatic memories, wasting syndrome, or withdrawal syndrome." Not too shabby. It's fun to imagine how many of these approximately 120 diseases and disorders -- five or ten years from now -- might well be treated with TS... This appears to have nothing to do with MNKD. The patent says for oral delivery, and MNKD is not involved in the patent. As far as I can see. What makes you think it is related to TS?
|
|
|
RLS
May 10, 2019 8:48:01 GMT -5
via mobile
peppy likes this
Post by mango on May 10, 2019 8:48:01 GMT -5
I don't think RLS can use MannKind's patent protected IP in their patents unless it's a joint patent or obtained the rights from MannKind to do so. But, MannKind already has the patents for cannabinoid-based technosphere formulations so it doesn't really matter unless RLS wants to use technosphere platform for other botanicals etc...
|
|
|
RLS
Jun 25, 2019 16:36:10 GMT -5
Post by goyocafe on Jun 25, 2019 16:36:10 GMT -5
Just curious, but as far as I can tell, the new Receptor Life Science website no longer references Mannkind or technosphere by name anywhere on the site. I remember the last iteration clearly called out Mannkind in its technology overview and possibly the news page. All that appears to have been eliminated. Can’t even get some love from our “partners”.
|
|